Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLUTO: Perioperative Toripalimab Plus Lenvatinib in RCC
NCT06114940Phase 2Terminated
- Sponsor
- Jinling Hospital
- Start
- Dec 2022
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, lenvatinib in renal cell carcinoma (RCC), sponsored by Jinling Hospital. Started Dec 2022; status: terminated.
02
Drugs
toripalimablenvatinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06114940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114940.